| Alzheimer Disease |
1 |
0.9 |
| Food and Drug Administration (FDA) |
0 |
0.65 |
| Traumatic Brain Injury |
0 |
0.48 |
| Aducanumab |
0 |
0.29 |
| Mild Cognitive Impairment |
0 |
0.27 |
| Cognitive Impairment |
0 |
0.23 |
| Brain |
0 |
0.21 |
| Impairment |
0 |
0.17 |
| Amyloid Plaque |
0 |
0.12 |
| Wound Management |
0 |
0.09 |
| Clinical Research |
0 |
0.08 |
| Injury |
0 |
0.08 |
| Statistics |
0 |
0.08 |
| Adverse Effects |
0 |
0.04 |
| Biologic Therapy |
0 |
0.04 |
| Drug Costs |
0 |
0.04 |
| Edema |
0 |
0.04 |
| Ethics |
0 |
0.04 |
| Geriatrics |
0 |
0.04 |
| Health Administration |
0 |
0.04 |
| Medicaid |
0 |
0.04 |
| Medicare |
0 |
0.04 |
| Monoclonal Antibody |
0 |
0.04 |
| Patient Safety |
0 |
0.04 |
| Post-Traumatic Stress Disorder |
0 |
0.04 |
| Professional Development |
0 |
0.04 |
| Stress |
0 |
0.04 |